ArticleInternational immunopharmacology2013
Optimized dosing of a CCR2 antagonist for amplification of vaccine immunity.
Article in International immunopharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 29 citations in OpenAlex.
- Pharmacological antagonism of Ccr2+ cell recruitment to facilitate regenerative tendon healing.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2025Article
- Pharmacological Antagonism of Ccr2+ Cell Recruitment to Facilitate Regenerative Tendon Healing.bioRxiv : the preprint server for biology · 2024Article
- CCR2-dependent CX3CR1+ colonic macrophages promoteInfection and immunity · 2024Article
- Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19.PLoS pathogens · 2022Review
- The role of macrophages during breast cancer development and response to chemotherapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020Review
- Cancer cell CCR2 orchestrates suppression of the adaptive immune response.The Journal of experimental medicine · 2020Article
- A novel cancer immunotherapy utilizing autologous tumour tissue.Vox sanguinis · 2020Article
- The Suppressive Attitude of Inflammatory Monocytes in Antiviral Antibody Responses.Viral immunology · 2020Review
- Pilot Acute Safety Evaluation of Innocell™ Cancer Immunotherapy in Canine Subjects.Journal of immunology research · 2020Article
- Tubular GM-CSF Promotes Late MCP-1/CCR2-Mediated Fibrosis and Inflammation after Ischemia/Reperfusion Injury.Journal of the American Society of Nephrology : JASN · 2019Article
- CaMKIIδ-mediated inflammatory gene expression and inflammasome activation in cardiomyocytes initiate inflammation and induce fibrosis.JCI insight · 2018Article
- Viral subversion of B cell responses within secondary lymphoid organs.Nature reviews. Immunology · 2018Review
- Monocyte differentiation and antigen-presenting functions.Nature reviews. Immunology · 2017Review
- Sphingosine 1-Phosphate- and C-C Chemokine Receptor 2-Dependent Activation of CD4Frontiers in immunology · 2017Article
- Murine Efficacy and Pharmacokinetic Evaluation of the Flaviviral NS5 Capping Enzyme 2-Thioxothiazolidin-4-One Inhibitor BG-323.PloS one · 2015Article
- Klotho gene deficiency causes salt-sensitive hypertension via monocyte chemotactic protein-1/CC chemokine receptor 2-mediated inflammation.Journal of the American Society of Nephrology : JASN · 2015Article
- Activation effects of polysaccharides of Flammulina velutipes mycorrhizae on the T lymphocyte immune function.Journal of immunology research · 2014Article
- Article
- Correlates of immune protection following cutaneous immunization with an attenuated Burkholderia pseudomallei vaccine.Infection and immunity · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
We have recently discovered that inflammatory monocytes recruited to lymph nodes in response to vaccine-induced inflammation can function as potent negative regulators of both humoral and cell-mediated immune responses to vaccination. Monocyte depletion or migration blockade can significantly amplify both antibody titers and cellular immune responses to vaccination with several different antigens in mouse models. Thus, we hypothesized that the use of small molecule CCR2 inhibitors to block monocyte migration into lymph nodes may represent a broadly effective means of amplifying vaccine immunity. To address this question, the role of CCR2 in monocyte recruitment to vaccine draining lymph nodes was initially explored in CCR2-/- mice. Next, a small molecule antagonist of CCR2 (RS102895) was evaluated in mouse vaccination models. Initial studies revealed that a single intraperitoneal dose of RS102895 failed to effectively block monocyte recruitment following vaccination. Pharmacokinetic analysis of RS102895 revealed a short half-life (approximately 1h), and suggested that a multi-dose treatment regimen would be more effective. We found that administration of RS102895 every 6 h resulted in consistent plasma levels of 20 ng/ml or greater, which effectively blocked monocyte migration to lymph nodes following vaccination. Moreover, administration of RS102895 with concurrent vaccination markedly enhanced vaccine responses following immunization against the influenza antigen HA1. We concluded that administration of small molecule CCR2 antagonists such as RS102895 in the immediate post-vaccine period could be used as a novel means of significantly enhancing vaccine immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.